ASCO 2024 – AstraZeneca’s GPC3 secret sauce
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
The sale of remaining rights to Allogene ends acrimony between the two companies.
A roundup of the first quarter's key oncology drug approvals and rejections.